Allogene Data Milestone Signals Potential Shift in LBCL Treatment
Event summary
- Allogene reported $258.3 million in cash and investments as of December 31, 2025, projecting runway into Q1 2028.
- The pivotal Phase 2 ALPHA3 trial for cema-cel in first-line large B-cell lymphoma (LBCL) will have an interim futility analysis in April 2026.
- Initial data from the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease is expected in June 2026.
- Allogene is exploring partnering opportunities for ALLO-316, currently in a Phase 1b cohort for renal cell carcinoma.
The big picture
Allogene's strategy hinges on demonstrating the efficacy and scalability of allogeneic CAR-T therapy, a potentially disruptive approach to cancer and autoimmune disease treatment. The ALPHA3 trial represents a high-risk, high-reward effort to redefine first-line LBCL treatment, while ALLO-329 aims to broaden the applicability of their Dagger® technology. The company's extended cash runway provides breathing room, but hinges on positive data readouts and potential partnerships to sustain operations.
What we're watching
- Clinical Outcomes
- The April 2026 interim futility analysis for ALPHA3 will be critical; failure to demonstrate meaningful MRD clearance could significantly impact the program's viability and Allogene's valuation.
- Manufacturing Scale
- Allogene's stated goal of delivering CAR-T at 'biologic-like scale' requires demonstrating efficient and cost-effective manufacturing processes, a persistent challenge for allogeneic therapies.
- Autoimmune Expansion
- The success of the ALLO-329 RESOLUTION trial, particularly the ability to reduce or eliminate lymphodepletion, will determine whether Allogene can meaningfully expand into the autoimmune disease market, a significantly larger addressable space than oncology.
Related topics